Clinical trial NCT00138125: Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer
Official title: Phase II Randomized Trial of Faslodex and Herceptin, Alone and Combined, in the First - Line Treatment of Hormone Receptor-Positive, HER-2/Neu-Overexpressing Metastatic Breast Cancer
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Breast Cancer
Keywords: stage IV breast cancer
recurrent breast cancer
Lead sponsor: Translational Oncology Research International
Sponsor class: OTHER
Collaborators: name: University of California, Los Angeles
name: Genentech, Inc.
name: AstraZeneca
First posted: 2005-08-30
Enrollment: 2
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using fulvestrant may fight breast cancer by lowering the amount of estrogen the body makes. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether giving fulvestrant together with trastuzumab is more effective than giving fulvestrant or trastuzumab alone in treating breast cancer.

PURPOSE: This randomized phase II trial is studying how well fulvestrant and/or trastuzumab works as first-line therapy in treating postmenopausal women with stage IV breast cancer.

Detailed description: OBJECTIVES:

Primary

* Compare the overall objective response rate in postmenopausal women with estrogen receptor (ER)- and/or progesterone receptor (PR)-positive, HER2/neu-overexpressing stage IV breast cancer treated with first-line therapy comprising fulvestrant and/or trastuzumab (Herceptin®).

Secondary

* Compare the duration of response in patients treated with these regimens.
* Compare overall survival of patients treated with these regimens.
* Compare the antitumor activity of these regimens, in terms of time to disease progression, in these patients.
* Compare the clinical benefit of these regimens in these patients.
* Determine the safety and toxicity of these regimens in these patients.
* Correlate HER2/neu expression and ER and/or PR expression with response in patients treated with these regimens.

OUTLINE: This is a randomized, controlled, open-label, multicenter study. Patients are stratified according to prior adjuvant endocrine therapy (yes vs no). Patients are randomized to 1 of 3 treatment arms.

* Arm I: Patients receive fulvestrant intramuscularly on days 1 and 15 of course 1 and then on day 1 only in all subsequent courses.
* Arm II: Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes on days 1, 8, 15, and 22.
* Arm III: Patients receive fulvestrant as in arm I in combination with trastuzumab as in arm II.

In all arms, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed every 8 weeks.

PROJECTED ACCRUAL: A total of 120 patients (40 per treatment arm) will be accrued for this study.

Eligibility criteria: Inclusion Criteria:

* Female patient, postmenopausal, defined as a woman fulfilling any one of the following criteria:

  * Age 60 years or older
  * Age 45 years or older with amenorrhea for \> 12 months with an intact uterus
  * Follicle-stimulating hormone and estradiol levels within post-menopausal range
  * Having undergone a bilateral oophorectomy
* Histologically or cytologically proven adenocarcinoma of the breast
* Subjects must have archived rumor tissue available to compare the clinical response with tumor expression of biomarkers, such as HER-2, ER and PR; archived tissue will be used to confirm HER-2, ER and PR status, but results will not be used to determine subject eligibility for the study
* HER2-positive disease
* ER-positive and/or PR-positive disease
* ECOG performance status 0-2
* Life expectancy \> 24 weeks
* Left ventricular ejection fraction \> lower limit of normal
* No prior chemotherapy, endocrine therapy, Herceptin, or other biologic or investigational therapy for metastatic breast cancer
* No more than two prior endocrine agents in the adjuvant setting as single- or sequential-therapy is permitted, but no prior Faslodex therapy is permitted. A 1-month treatment-free period is required prior to receiving the first dose of trial treatments
* Prior adjuvant chemotherapy is permitted
* Prior adjuvant Herceptin permitted
* At least 1 month since prior surgery, radiotherapy, or endocrine therapy, with complete recovery from the effects of these interventions
* Patients must have ended any hormone replacement therapy at least 1 month prior to receiving the first dose of trial therapy
* Patients treated with bisphosphonates may enroll, with heir bone lesions only assessable for disease progression
* Patient is accessible and willing to comply with treatment and follow-up
* Patient is willing to provide written informed consent prior to the performance of any study-related procedures
* Required laboratory values:

  * Absolute neutrophil count \> 1.5 x 10\^9/L
  * Hemoglobin \> 10g/dL
  * Platelet count \> 100 x 10\^9/L
  * Creatinine \< 2.0 mg/dL
  * Total bilirubin \< 1.5 x upper limit of normal
  * AST and ALT \< 2.5 x ULN

Exclusion Criteria:

* Prior chemotherapy, hormonal therapy, Herceptin or other investigational therapy for metastatic breast cancer
* Prior treatment with Faslodex
* Concurrent therapy with any other non-protocol anti-cancer therapy
* Current or prior history of brain metastases
* History of any other malignancy within the past 5 years, with the exception of non-melanoma skin cancer or carcinoma-in-situ of the cervix
* Clinically significant cardiovascular disease, New York Heart Association Class II or greater congestive heart failure, or serious cardiac arrhythmia requiring medication
* Prior exposure of \> 360 mg/m2 doxorubicin or liposomal doxorubicin, \> 120 mg/m2 mitoxantrone, \> 90 mg/m2 idarubicin, or \> 720 mg/m2 epirubicin
* Active, uncontrolled infection requiring parenteral antimicrobials
* The presence of any other medical or psychiatric disorder that, in the opinion of the treating physician, would contraindicate the use of the drugs in this protocol or place the subject at undue risk for treatment complications
* Inability to comply with the study protocol or follow-up procedures
* Known hypersensitivity to any of the drugs used in this protocol or to active or inactive excipients of Faslodex
* History of bleeding diasthesis
* Long-term anticoagulant therapy other than anti-platelet therapy, such as with warfarin

Primary outcomes:
measure: Progression-free Survival
timeFrame: 5 years
Secondary outcomes:
measure: Overall Objective Response Rate
timeFrame: 5 years
measure: Time to Tumor Progression
timeFrame: 5 years
measure: Duration of Response
timeFrame: 5 years
measure: Overall Survival
timeFrame: 5 years
measure: Clinical Benefit (CR + PR + SD > 6 Months)
timeFrame: 5 years
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: Jonsson Comprehensive Cancer Center at UCLA
state: California
city: Redondo Beach
country: United States
facility: Cancer Care Associates Medical Group, Inc
state: California
city: San Antonio
country: United States
state: Texas
Study officials:
affiliation: Jonsson Comprehensive Cancer Center
name: Richard J. Pietras, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: